Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Autor: Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabeta Gherga, France Nguyen, Cédrik Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Lars Damstrup, Philippa Crompton, Abdallah Ennaji, Kathrin Gollmer, Heidi Nauwelaerts, Jean Bourhis

Publikováno v: European Journal of Cancer
European Journal of Cancer, 2023, 183, pp.24-37. ⟨10.1016/j.ejca.2022.12.015⟩
Tao, Yungan; Sun, Xu-Shan; Pointreau, Yoann; Le Tourneau, Christophe; Sire, Christian; Kaminsky, Marie-Christine; Coutte, Alexandre; Alfonsi, Marc; Calderon, Benôit; Boisselier, Pierre; Martin, Laurent; Miroir, Jessica; Ramee, Jean-Francois; Delord, Jean-Pierre; Clatot, Florian; Rolland, Frederic; Villa, Julie; Magne, Nicolas; Elicin, Olgun; Gherga, Elisabeta; ... (2023). Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European journal of cancer, 183, pp. 24-37. Elsevier 10.1016/j.ejca.2022.12.015

International audience; Introduction: We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211a0df94cec42ecc06dd2e0c99d51be

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Autor: Mirjam Kuipers, Ivan Diaz-Padilla, Morten Mau-Sørensen, Barbara Sarholz, Maja J.A. de Jonge, Dorte Nielsen, Ahmad Awada, Henk M.W. Verheul, Karin Berghoff, Jan H.M. Schellens, Lars Damstrup, Samer El Bawab, Patrick Schöffski, Mark T. J. van Bussel

Publikováno v: British Journal of Cancer, 124, 728-735
van Bussel, M T J, Awada, A, de Jonge, M J A, Mau-Sørensen, M, Nielsen, D, Schöffski, P, Verheul, H M W, Sarholz, B, Berghoff, K, El Bawab, S, Kuipers, M, Damstrup, L, Diaz-Padilla, I & Schellens, J H M 2021, ' A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours ', British Journal of Cancer, vol. 124, no. 4, pp. 728-735 . https://doi.org/10.1038/s41416-020-01151-6
British Journal of Cancer
British Journal of Cancer, 124, 4, pp. 728-735

Background: This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of peposertib (formerly M3814), a DNA-dependent protein kinase (DNA-PK) inhibitor in patients with adv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a65e8cb8640861d31d96ecf577c12d9
https://hdl.handle.net/2066/232010

A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results

Autor: Rainer Strotman, Sanjay Goel, Mark T. J. van Bussel, Michael A. Samuels, Johan Falkenius, Baukelien van Triest, Juergen Debus, Morten Sorensen, Karin Berghoff, Volker Budach, Lars Damstrup, Poul F. Geertsen, Esther G.C. Troost

Publikováno v: Journal of Clinical Oncology. 36:2518-2518

2518Background: DNA-dependent protein kinase (DNA-PK), regulates one of the major pathways responsible for repair of DNA double-strand breaks. The combination of RT and DNA-PK inhibition (DNA-PKi) ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01d4349a04f217232382c3ba10f6f4ef
https://doi.org/10.1200/jco.2018.36.15_suppl.2518

Abstract 4183: A novel selective DNA-PK inhibitor, M3814, as a potential combination partner of Etoposide and Cisplatin in the therapy of lung cancer

Autor: Astrid Zimmermann, Thomas Grombacher, Frank Zenke, Sirrenberg Christian, Lyubomir T. Vassilev, Lars Damstrup, Andree Blaukat

Publikováno v: Cancer Research. 77:4183-4183

M3814 is a potent and selective inhibitor of DNA-PK, one of the key cellular regulators of DNA damage induced by ionizing radiation or certain cytostatics used in the treatment malignant disease. One of these drugs, Etoposide, induces double strand b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01b856ae326fde08e3a1ee657f2c9c0f
https://doi.org/10.1158/1538-7445.am2017-4183

Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis

Autor: Peter J. Dempsey, Hans Skovgaard Poulsen, C J Hawkey, Lars Damstrup, Robert J. Coffey, H. S. Wiley, S K Kuwada, Christa L. Brown

Publikováno v: British Journal of Cancer

Colonic enterocytes, like many epithelial cells in vivo, are polarized with functionally distinct apical and basolateral membrane domains. The aims of this study were to characterize the endogenous epidermal growth factor (EGF)-like ligands expressed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::790d75ad1848026e1b5d6cca30c89d63
http://europepmc.org/articles/PMC2363033